A review of the technique has been submitted for publication in a peer reviewed journal. It demonstrates the safety of the treatment. It also quantifies autonomic symptom response of over 90%. While not everyone will respond, and in some patients the response may be of limited duration, we do see that the majority of patients have a durable response. A review of approximately 400 of our patients demonstrated that 75% have improving or stable symptoms at 6 months and beyond.
What's confusing to me is that he includes 400 patients. There is no way that he saw 400 MS patients who all had unstenosed veins. If the patients had stenosed veins, then there is no way to tell if the effects of the procedure are due to the proposed TVAM impact on the nerve or due to the improved flow resulting from the removal of a stenosis. If the paper included the data only on patients who were treated exclusively in nonstenosed veins or allows for an analysis of that data set, then his results could be evaluated without that confounding variable.
I have all along liked his use of HRV heart rate variability testing. It's a measurement of autonomic nervous system dysfunction.